Fig. 3.

The first ¹⁸F-FDG PET study (February 13, 2019) is illustrated by the images above (a1-a7) while the second study (December 22, 2020) produced the images below (b1-b7). (a1-a5, b1-b5 axial sections; a6, b6 sagittal sections; a7, b7 coronal sections). ¹⁸F-FDG PET studies showed a marked reduction in radiopharmaceutical uptake in the parietal (a2-a4; b2-b4), lateral temporal (a1; b1) and prefrontal regions bilaterally (a5, a6; b5, b6), greater in the right hemisphere. The uptake was also significantly reduced at the level of the precuneus (a6; b6), especially on the right side, and slightly impaired at the level of the cingulate (a6; b6) and of the occipital lobe (a4, a5, a7; b4, b5, b7). The comparison between the two studies shows a accentuation of hypometabolism in the same areas after about 22 months (b1-b8).